Welcome guest, Login | Register


Petra Baumgaertner


PhD in Biochemistry at the JW Goethe University, Frankfurt, Germany, 1998


  1. Hebeisen, M., Schmidt, J., Guillaume, P., Baumgaertner, P., Speiser, D. E., Luescher, I. and Rufer, N. (2015). Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells. Cancer Res 75(10): 1983-1991.

  2. Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E. and Speiser, D. E. (2014). Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 63(3): 247-257.

  3. Mahnke, Y. D., Devevre, E., Baumgaertner, P., Matter, M., Rufer, N., Romero, P. and Speiser, D. E. (2012). Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology 1(4): 467-530.

  4. Lovgren, T., Baumgaertner, P., Wieckowski, S., Devevre, E., Guillaume, P., Luescher, I., Rufer, N. and Speiser, D. E. (2012). Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol Immunother 61(6): 817-826.

  5. Baumgaertner, P., Jandus, C., Rivals, J. P., Derre, L., Lovgren, T., Baitsch, L., Guillaume, P., Luescher, I. F., Berthod, G., Matter, M., Rufer, N., Michielin, O. and Speiser, D. E. (2012). Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer 130(11): 2607-2617.

  6. Speiser, D. E., Wieckowski, S., Gupta, B., Iancu, E. M., Baumgaertner, P., Baitsch, L., Michielin, O., Romero, P. and Rufer, N. (2011). Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc Natl Acad Sci U S A 108(37): 15318-15323.

  7. Speiser, D. E., Baumgaertner, P., Voelter, V., Devevre, E., Barbey, C., Rufer, N. and Romero, P. (2008). Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 105(10): 3849-3854.

Protocols by Petra Baumgaertner
  1. Chromium-51 (51Cr) Release Assay to Assess Human T Cells for Functional Avidity and Tumor Cell Recognition